Welcome to our dedicated page for Nanoviricides SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NanoViricides, Inc. filings document the formal disclosures of a clinical-stage antiviral drug developer listed on NYSE American under the symbol NNVC. The company’s SEC record covers material events, proxy governance, stockholder voting matters and capital-raising transactions tied to its common stock and other securities.
Recent filings include Form 8-K reports on annual-meeting voting results, a registered direct offering involving common stock and pre-funded warrants, and officer compensation arrangements. Proxy materials describe board elections, advisory compensation votes, auditor ratification and related governance procedures. The filings also identify capital-structure elements such as common stock, Series A convertible preferred stock and shelf-registration-based financing activity.
NanoViricides, Inc. filed a shelf registration on Form S-3 to offer up to $50,000,000 of various securities, including common stock, preferred stock, debt, warrants, rights and units, with specific terms to be set in prospectus supplements.
The prospectus states 22,982,816 shares of Common Stock outstanding as of June 4, 2026, 918,422 shares of Series A Preferred outstanding, and an aggregate market value of Common Stock held by non-affiliates of approximately $35,500,000 based on a $1.59 closing price on June 2, 2026.
NanoViricides, Inc. reported that its President and Executive Chairman, Dr. Anil R. Diwan, participated in the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, in a fireside chat with A.G.P. equity research analyst Dr. James Molloy.
During the discussion, Dr. Diwan described two antiviral drug candidates developed during COVID-19: NV-387, a broad-spectrum antiviral now entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo, and a backup candidate where remdesivir is encapsulated within NV-387 nanoviricide micelles as an oral formulation.
He explained that remdesivir has prior Ebola clinical trial and safety data, that NV-387 encapsulation is designed to protect remdesivir from rapid metabolism based on animal studies and a peer‑reviewed PLOS One publication, and that the company maintains both NV-387 alone and NV-387 with remdesivir as candidates the company expects could address the current Ebola Bundibugyo strain in DRC, subject to public health authorities’ decisions.
NanoViricides, Inc. entered into a registered direct offering with a single institutional investor, raising approximately $2.0 million in gross proceeds through common shares or pre-funded warrants plus accompanying common warrants. The securities were priced at $1.50 per share (or $1.49999 per pre-funded warrant), with warrants to purchase 1,333,334 shares at an exercise price of $1.75 per share.
The financing closed after effectiveness of the company’s Form S-3 shelf registration and includes a 30-day restriction on most new equity issuances, a 10-day pause on at-the-market sales, and a 30-day CEO lock-up. NanoViricides plans to use net proceeds for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions or other strategic purposes.
NanoViricides, Inc. is conducting a registered direct offering of 1,333,334 shares of Common Stock, pre-funded warrants to purchase up to 200,000 shares and common warrants to purchase up to 1,333,334 shares at stated prices. The shares are offered at $1.50 per share, pre-funded warrants at $1.49999 each and common warrants exercisable at $1.75. Net proceeds to the company are expected to be approximately $1.735M, and delivery is expected on or about May 18, 2026. The prospectus supplement notes 22,780,334 shares outstanding immediately after the Offering and discloses a going-concern qualification tied to cash needs and anticipated future financings.
NanoViricides, Inc. is conducting a registered direct offering of 1,333,334 shares of Common Stock, pre-funded warrants to purchase up to 200,000 shares and common warrants to purchase up to 1,333,334 shares at stated prices. The shares are offered at $1.50 per share, pre-funded warrants at $1.49999 each and common warrants exercisable at $1.75. Net proceeds to the company are expected to be approximately $1.735M, and delivery is expected on or about May 18, 2026. The prospectus supplement notes 22,780,334 shares outstanding immediately after the Offering and discloses a going-concern qualification tied to cash needs and anticipated future financings.
NanoViricides, Inc. reported continued operating losses in its quarter and nine months ended March 31, 2026, while advancing its broad-spectrum antiviral NV‑387. Net loss was $1,989,333 for the quarter and $5,995,110 for the nine months, driven by $6,060,077 in operating expenses.
The company had cash and cash equivalents of $3,213,256 and total assets of $10,219,004, against total liabilities of $1,065,407 and an accumulated deficit of $154,836,971. Management states there is substantial doubt about its ability to continue as a going concern, as existing cash and a $3,000,000 related-party credit line are not expected to fund operations for 12 months.
To support liquidity, NanoViricides raised approximately $1,909,000 net via an at-the-market offering and $5,403,981 net through a Registered Direct Offering and concurrent private placement of warrants. As of May 14, 2026, there were about 21,647,000 common shares outstanding and 7,147,720 warrants outstanding.
NV‑387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events and was granted U.S. FDA Orphan Drug Designation on April 27, 2026 for the treatment of Measles, positioning it for potential orphan-focused development paths.
NanoViricides, Inc. reported a net loss of $4.0 million for the six months ended December 31, 2025, improving from a $5.2 million loss a year earlier as operating expenses declined. The company remains a clinical-stage antiviral developer with no revenue to date.
Cash and cash equivalents rose to $5.2 million from $1.6 million at June 30, 2025, driven by equity financings and a $6.0 million registered direct and private placement transaction, leaving stockholders’ equity at $11.1 million. However, management states that existing cash and an undrawn $3.0 million related-party credit line are not sufficient to fund planned operations for at least 12 months, and they conclude that substantial doubt exists about the company’s ability to continue as a going concern.
The lead broad-spectrum antiviral candidate NV-387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events, and the company is preparing Phase II studies, including for MPox and viral respiratory infections. NanoViricides is also pursuing orphan drug designations in the United States for NV-387 in Measles, MPox, and Smallpox while continuing development of its herpes-focused NV-HHV-1 program and maintaining extensive license arrangements with related-party TheraCour Pharma for multiple viral indications.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of Series A warrants for 3,571,429 shares at $1.75 per share and Series B warrants for 3,571,429 shares at $2.00 per share, all originally issued in a November 10, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $13.4 million in gross proceeds if all the warrants are exercised for cash.
NanoViricides is a clinical-stage company developing antiviral drugs based on its nanoviricides platform. Lead candidate NV-387 has completed a Phase Ia/Ib safety trial with no reportable adverse events and is being advanced toward Phase II trials for MPox and viral acute and severe-acute respiratory infections. As of mid‑December 2025, 21,568,429 shares of common stock were outstanding, with additional preferred shares and warrants reserved for future issuance.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a selling stockholder, representing shares underlying Series A and Series B common stock purchase warrants.
The warrants, issued in a November 10, 2025 private placement, are exercisable at $1.75 and $2.00 per share and, if fully exercised for cash, could provide the company with approximately $13.4 million in gross proceeds, though the company will not receive any proceeds from resale of the shares themselves. The sole selling stockholder, Armistice Capital Master Fund, Ltd., beneficially owns 10,714,287 shares and is subject to a 4.99% beneficial ownership limitation on warrant exercises. As of November 10, 2025, NanoViricides had 21,568,429 common shares outstanding, and its most recent audited financial statements include an explanatory paragraph noting substantial doubt about the company's ability to continue as a going concern.